DK3220947T3 - Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf - Google Patents

Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf Download PDF

Info

Publication number
DK3220947T3
DK3220947T3 DK15798327.1T DK15798327T DK3220947T3 DK 3220947 T3 DK3220947 T3 DK 3220947T3 DK 15798327 T DK15798327 T DK 15798327T DK 3220947 T3 DK3220947 T3 DK 3220947T3
Authority
DK
Denmark
Prior art keywords
viruses
potentally
antibodies
light
neutralize rabies
Prior art date
Application number
DK15798327.1T
Other languages
English (en)
Inventor
Hervé Bourhy
Davide Corti
Original Assignee
Humabs Biomed S A
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed S A, Pasteur Institut filed Critical Humabs Biomed S A
Application granted granted Critical
Publication of DK3220947T3 publication Critical patent/DK3220947T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15798327.1T 2014-11-18 2015-11-18 Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf DK3220947T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2014003076 2014-11-18
PCT/EP2015/002305 WO2016078761A1 (en) 2014-11-18 2015-11-18 Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof

Publications (1)

Publication Number Publication Date
DK3220947T3 true DK3220947T3 (da) 2020-11-30

Family

ID=52339085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15798327.1T DK3220947T3 (da) 2014-11-18 2015-11-18 Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf

Country Status (13)

Country Link
US (4) US10703801B2 (da)
EP (2) EP3220947B1 (da)
CN (2) CN114805558B (da)
BR (2) BR122020023406B1 (da)
DK (1) DK3220947T3 (da)
ES (1) ES2838679T3 (da)
HR (1) HRP20201811T1 (da)
HU (1) HUE052595T2 (da)
LT (1) LT3220947T (da)
PH (2) PH12017500722A1 (da)
PL (1) PL3220947T3 (da)
SI (1) SI3220947T1 (da)
WO (1) WO2016078761A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
WO2020078568A1 (en) * 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
MX2021005029A (es) * 2018-11-02 2021-07-15 Cadila Healthcare Ltd Anticuerpos monoclonales antirabicos y combinados de los mismos.
CN109970852B (zh) * 2019-04-01 2020-10-13 浙江大学 分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用
WO2022090484A2 (en) * 2020-10-29 2022-05-05 The Secretary Of State For Environment, Food And Rural Affairs Viral vector
CN114958774B (zh) * 2022-05-08 2023-10-27 中国医学科学院医学生物学研究所 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用
CN117683123A (zh) * 2023-09-15 2024-03-12 东普安凤(北京)生物技术有限公司 抗狂犬病毒人源化抗体和抗体组合及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
PL1851315T3 (pl) * 2005-02-02 2014-06-30 Univ Massachusetts Ludzkie przeciwciała przeciwko wściekliźnie i ich zastosowania
DK2350128T3 (da) 2008-10-22 2014-12-01 Inst Research In Biomedicine Fremgangsmåder til fremstilling af antistoffer fra plasmaceller
WO2011080765A2 (en) * 2010-01-04 2011-07-07 Indian Immunologicals Limited Recombinant human bivalent diabody against rabies virus and uses thereof
EP2630242B1 (en) * 2010-10-19 2017-08-02 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Identification of antibodies specific for lyssaviruses
JP5868549B2 (ja) * 2012-05-24 2016-02-24 マウントゲイト グループ リミテッド 狂犬病感染の予防および治療に関する組成物および方法

Also Published As

Publication number Publication date
BR112017010298A2 (pt) 2017-12-19
LT3220947T (lt) 2020-12-28
HUE052595T2 (hu) 2021-05-28
CN107428819A (zh) 2017-12-01
US11730813B2 (en) 2023-08-22
PH12021550521A1 (en) 2022-02-14
PH12017500722A1 (en) 2017-10-09
US10703801B2 (en) 2020-07-07
CN114805558A (zh) 2022-07-29
HRP20201811T1 (hr) 2021-01-08
EP3220947B1 (en) 2020-10-28
US20240050565A1 (en) 2024-02-15
ES2838679T3 (es) 2021-07-02
US11723977B2 (en) 2023-08-15
US20200354435A1 (en) 2020-11-12
EP3831404A1 (en) 2021-06-09
EP3220947A1 (en) 2017-09-27
BR122020023406B1 (pt) 2023-10-31
BR112017010298B1 (pt) 2023-10-31
SI3220947T1 (sl) 2021-02-26
WO2016078761A1 (en) 2016-05-26
US20200354436A1 (en) 2020-11-12
PL3220947T3 (pl) 2021-05-31
US20180105579A1 (en) 2018-04-19
CN114805558B (zh) 2023-12-29
CN107428819B (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
DK3400291T3 (da) Manipuleret virus
DK3393510T3 (da) Zikavirusvaccine
DK3366295T3 (da) Fremgangsmåder til behandling af filoviridae virusinfektioner
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3218519T3 (da) Multipass-sekvensering
DK3220947T3 (da) Antistoffer som potent neutraliserer rabiesvirus og øvrige lyssavirusser og anvendelser deraf
DK3250593T3 (da) Anti-transthyretin-antistoffer
BR112016017471A2 (pt) corta-chamas
DK3365629T3 (da) H-formet vaterpas
DK3347307T3 (da) Fremgangsmåde til ekstraktionen af silikat
BR112015022362A2 (pt) roda
DK3356091T3 (da) Ledindretning
DK3148993T3 (da) Fremgangsmåde til fremstilling af thiazolderivater
DK3259549T3 (da) Lyssporammunition
CL2014001800S1 (es) Vaso
DK3143028T3 (da) Fremgangsmåde til fremstilling af penamer
FI20145263A (fi) Tilauksen varmentaminen
IT201600077076A1 (it) Bicchiere
FI10566U1 (fi) Selektiivilasi
TH1601002469A (th) ลำดับ kz144 เอนโดไลซินที่ถูกดัดแปลง
TH1601003274A (th) กระจกดูดกลืนรังสีอุลตร้าไวโอเลต
ES1138782Y (es) Gresite luminoso
TH1601003730A (th) แอนติ-vista แอนติบอดี และชิ้นส่วนย่อย
TH1501007185A (th) ไวรัสและวัคซีน
TH1501007814B (th) ชุดกระจกจำกัดแสงอาทิตย์